November 20, 2014

FY2015 Q2 Review

Safe Harbor Statement

2

This presentation includes forward looking statements.‐Forward looking statements may be identified by the use of forward looking terminology, including “may,” ‐ ‐“believe,” “will,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” and “forecast,” or other similar words.Statements in this presentation are based on information presently available to us and assumptions that we believe to be reasonable.Investors are cautioned that all such statements involve risks and uncertainties.Forward looking statements in this presentation include statements concerning:‐• Building stockholder value;• Achieving consistent sales and profitability targets and growth worldwide;• Achieving clinical, regulatory, product development and market development projects and goals; • Evaluating and advancing other medical device and neuroscience opportunities;• Completing the stock repurchase program; and• Fiscal guidance for fiscal year 2015

Our actual results may differ materially.For a detailed discussion of the factors that may cause our actual results to differ, please refer to our most recent filings with the SEC, including our Annual Report on Form 10 K for the fiscal year ended April 25, ‐2014 and Quarterly Report on Form 10-Q for the fiscal period ended July 25, 2014.

TOPICS

Highlights

FY15 Q2 OverviewSalesFinancials

Strategic Focus Update

FY15 Guidance

3

Quarterly Highlights and Performance

4

* The company refers and makes comparisons to non-GAAP financial measures in this presentation: EBITDA, adjusted net income and adjusted income per diluted share. Investors should consider non-GAAP measures in addition to, and not as a substitute for or superior to, financial performance measures prepared in accordance with GAAP. Please refer to the reconciliation between GAAP and non-GAAP measures for EBITDA, adjusted net income and adjusted Income per diluted share included in our earnings release dated November 20, 2014.

• Continued growth and leverage

Net Product Sales $73 million 5%

U.S. $60 million 4%

International $13 million 10%

Operating Income $26 million 20%

EBITDA $30 million 18%

Adjusted Income per diluted share $0.63 26% *

• Regulatory approval of ProGuardianREST™ System in Europe• Vitaria™ generator submission completed for CE mark (chronic heart failure)

• AspireSR ™ generator regulatory submission to FDA

Sales

5

FY15 Q2 Net Sales

6

• Solid international growth

*On a constant currency basis, international sales revenue grew by 13%

- Numbers in $000s- Represents revenue from sales of generators, leads, and other related devices

*

% Change

U.S. 56,358 57,882 53,020 58,194 58,838 59,939 3.6%International 11,047 12,219 13,071 14,009 13,166 13,479 10.3%

$67,404 $70,101 $66,091 $72,203 $72,004 $73,417 4.7%

Single Country Order 2,100 2,646

Net Product Sales $67,404 $70,101 $68,191 $74,849 $72,004 $73,417 4.7%

Licensing Total 1,468

Net Sales Total $68,872 $70,101 $68,191 $74,849 $72,004 $73,417 4.7%

FY 2015

Q1 Q2 Q3 Q4

FY 2014

Q2 FY15 vs. Q2 FY14

Q1 Q2

$10.0

$20.0

$30.0

$40.0

$50.0

$60.0

$70.0

Q1 Q2 Q3 Q4

Net

Pro

duct

Sal

es($

mill

ion)

Continued Worldwide Net Product Sales Growth

7

- Represents revenue from sales of generators, leads, and other related devices

$73.4M

• Year-over-year sales increases

FY15 Q2 Unit Sales

8

• Strong international growth

% Change

U.S. 2,455 2,518 2,259 2,482 2,500 2,525 0.3%International 899 978 1,050 1,115 1,024 1,081 10.5%

3,354 3,496 3,309 3,597 3,524 3,606 3.2%

Single Country Order 100 126

Unit Sales Total 3,354 3,496 3,409 3,723 3,524 3,606 3.2%

Q2Q1

FY 2014 FY 2015Q2 FY15 vs.

Q2 FY14Q2 Q3 Q4 Q1

Q1 Q2 Q3 Q4

1,000

1,200

1,400

1,600

1,800

2,000

2,200

2,400

2,600

FY10FY11

FY12FY13

FY14FY15

U.S

. Uni

t Sal

es o

f Gen

erat

ors

U.S. Unit Sales Growth

9

2,525

Q1 Q2 Q3 Q4

$10,000

$12,000

$14,000

$16,000

$18,000

$20,000

FY10FY11

FY12FY13

FY14FY15

ASP

of U

.S. G

ener

ator

s

Consistent U.S. ASP Growth for Generators

10

$20,550

• Increase of 4% over Q2 prior year

Financials

11

FY15 Q2 Financial Results*

12

- All numbers in $000s except for income per share

* Please refer to the reconciliation between GAAP and non-GAAP measures for EBITDA, adjusted net income and adjusted income per diluted share included in our earnings release dated November 20, 2014.

Q2 FY15 Q2 FY14

Net Sales $73,417 $70,101 4.7 %

Gross Profit 66,651 63,175 5.5 %Gross Profit % 90.8% 90.1%

SG&A 29,573 29,634 (0.2)%R&D 10,817 11,653 (7.2)%

Total Operating Expenses 40,390 41,287 (2.2)%

Income From Operations $26,262 $21,888 20.0 %

Income tax expense 9,025 8,004 12.8 %

Net Income $17,273 $13,888 24.4 %

Outstanding shares - diluted 26,792 27,579 (2.9)%

Diluted income per share $0.64 $0.50 28.0 %

% Change

Reconciliation of Non-GAAP Financial Measures

13

- All numbers in $000s except for income per share

Q2 FY15 Q2 FY14

Net income $17,273 $13,888 24.4%Change in reserve for prior year R&D tax credits (1,301) R&D tax credit not enacted 223 Reserve for prior year international tax liabilities 744

Adjusted non-GAAP net income $16,939 $13,888 22.0%

Diluted income per share $0.64 $0.50 28.0%Change in reserve for prior year R&D tax credits (0.05) R&D tax credit not enacted 0.01 Reserve for prior year international tax liabilities 0.03

Adjusted non-GAAP diluted income per share $0.63 $0.50 26.0%

% change

Financial and Business Highlights

Sales • Double digit international revenue and unit growth• New highs for U.S. units and revenue• Ongoing ASP growth

Financial leverage • Adjusted net income increase of 22%• Adjusted EPS growth of 26%

Industry-leading margins

• Gross margin of 91%• Operating margin of 36%• Adjusted EBITDA margin of 41%

Strong balance sheet and cash flow

• $142m in cash and short term investments• Stockholders equity of $270M• Adjusted LTM EBITDA of $111M

14

Strategic Focus

15

Product Development Program

AspireSR® Generator • Continued adoption in Europe & Middle East• Submitted to FDA for approval

ProGuardianRESTTM

System• Received EU regulatory clearance• Limited commercial release planned

CentroTM Generator • Utilizes wireless communication technology• Regulatory submissions expected in FY2015

Autonomic Regulation Therapy for chronic heart failure

• Results presented on September 1st

• VITARIATM submission completed• First patient implanted in HFpEF study

16

FY15 Goals Update

17

Build shareholder value through:

Continued leadership in epilepsy medical devices

Consistent sales and profitability growth worldwide

Achieving clinical and product development milestones

ProGuardianREST™ regulatory submissionsCentro™ regulatory submissionsAspireSR® generator U.S. regulatory progress

Evaluating and advancing other neuroscience opportunitiesCHF regulatory submission in Europe

FY15 Guidance

18

Fiscal FY2015 Guidance – Net Sales Updated

19

Net Sales

$96 million - $99 million

$292 million - $298 million 7%

Adjusted Income from Operations

$62 million - $64 millionAdjusted Net Income

$2.33 - $2.39Adjusted EPS

11%

12%

16%

% change FY14 Adjusted

vs FY15 Midpoint

*FY14 net sales adjusted for Single Country Order and Licensing Revenue

*

(Previous net sales guidance: $300 million - $307 million)

20

For additional information, please contact:

Investor Relationsir@cyberonics.com

www.cyberonics.comNASDAQ:CYBX